1d
MedPage Today on MSNApproved Sickle Cell Drug Fails to Beat Placebo in TrialCrizanlizumab (Adakveo) failed to outperform placebo in patients with sickle cell disease, the phase III STAND trial showed.
In the second trial, which was open label, 95.6% of participants who switched to DOR/ISL maintained viral suppression ...
Proportion increases when considering off-label use but drops when considering drugs with substantial clinical benefit.
After failing to hit the primary endpoint in a Phase III trial, Neumora is remixing study parameters in two replicate trials, ...
We think it can be appropriate to present phase 2 trial participation as offering a small prospect of benefit,” researchers wrote. About 16% of patients enrolled in phase 2 cancer trials receive a ...
17h
Clinical Trials Arena on MSNBioCity and MSD to evaluate cancer treatment combination in Phase I/II trialBioCity Biopharmaceuticals and MSD have signed a clinical trial partnership agreement to assess BC3195 in conjunction with ...
The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...
In an alopecia areata trial, a novel bifunctional therapy that blocks signaling of the interleukin-7 and TSLP pathways ...
CervoMed has announced positive results from the extension phase 2b RewinD-LB study of neflamapimod for dementia with Lewy ...
Mineralys Therapeutics' lorundrostat met key Phase 3 and Phase 2 trial endpoints for hypertension, showing significant blood ...
Patients enroll in phase 2 oncology trials seeking access to promising new treatments, but the risk-benefit assessments and ...
Amgen’s $400 million eczema drug candidate has recorded two more phase 3 victories. The data drops provide more evidence that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results